Neurophth announces first patient dosed in Phase III clinical trial for the gene therapy treatment of LHON

Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day

Neurophth Ranked as One of the MIT 50 Smartest Companies 2021

China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth’s NR082 in LHON

Neurophth Therapeutics and Abogen Biosciences Announce Strategic Partnership to Develop mRNA-Based Therapies for the Treatment of Retinal Diseases

The 3rd BIO International Convention 2022 is Approaching

Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA

Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy